Walter Schloss: All Superinvestors Make Mistakes of Omission

The Acquirer’s Multiple®  |


The Annual Ben Graham Conference was held earlier this year and the topic was – investing mistakes. The panel members were Edwin Schloss, son of Walter Schloss, Paul Lountzis – President Lountzis Management, and Michael Lipper – President Lipper Advisory Services.

Edwin Schloss shared a couple of great anecdotes on how he and his father made two very big mistakes of ommission by not getting in early on Apple  (AAPL) stock in 2009/2010, then called Apple Computers when it was $11, and Xerox  (XRX) in the 1950’s, which was then called The Haloid Photographic Company.

Here’s an except from that conference which you can watch in the video below [23:00]:

Edwin Schloss: This is so embarrassing. In 2009/2010 my dad and I looked at Apple. It was called Apple Computer in those days. It was selling below its cash levels. The stock was around $11. My dad and I never really did technology. Every time we bought technology we always seemed to do poorly because we were always buying the also-ran. We never seemed to be buying the one that everybody was… We’re not exactly momentum players. Put it that way. We didn’t buy Apple and I see what it is now. I didn’t realise how incredible an investment it would have been.

But, I have to tell you that my dad had a very interesting experience when he worked for Benjamin Graham in the fifties. Ben had come back from lunch one day and said, “Walter what are you working on now. I’d like to see a new idea for me”. So Walter said, “Well, I have a very interesting idea here. I’m working on a company called Haloid.” Ben said, “What is it exactly”. Walter said, “This is a company that was founded in 1906, a Rochester company, and it looks very interesting. Has to do with reproduction, photo reproduction”. Ben said, “This is not an area we usually invest in. It’s not a rail, it’s not a utility, it seems to me this is a new area, this technology thing. I don’t really know if we should do it”. And of course Haloid turned into Xerox. The reason I recall that anecdote is that it’s apropos that I think for value people its very difficult to invest in technology effectively.

Here’s the video of the Annual Ben Graham Conference 2018.

For more articles like this, check out our recent articles here.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.